{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:42:34Z","timestamp":1785307354720,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["NC DHHS GTS #49927"],"award-info":[{"award-number":["NC DHHS GTS #49927"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["75D30120C08405"],"award-info":[{"award-number":["75D30120C08405"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T02:46:29Z","timestamp":1678329989000},"page":"2596-2604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March\u2013October, 2021"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-381X","authenticated-orcid":false,"given":"Ian D.","family":"Plumb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida M.","family":"Fette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-5071","authenticated-orcid":false,"given":"Ashley H.","family":"Tjaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-6760","authenticated-orcid":false,"given":"Leora","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Saydah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-4363","authenticated-orcid":false,"given":"Amina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-806X","authenticated-orcid":false,"given":"Ruth","family":"Link-Gelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Wierzba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-3868","authenticated-orcid":false,"given":"Andrea A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-4643","authenticated-orcid":false,"given":"DeAnna","family":"Friedman-Klabanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira P.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-4317","authenticated-orcid":false,"given":"Michael S.","family":"Runyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-3427","authenticated-orcid":false,"given":"Roberto P.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-6234","authenticated-orcid":false,"given":"Johnathan","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-4404","authenticated-orcid":false,"given":"Sharon","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-796X","authenticated-orcid":false,"given":"Diane","family":"Uschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.006_b0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.03.006_b0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.03.006_b0015","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.abm3087","article-title":"Indirect protection of children from SARS-CoV-2 infection through parental vaccination","volume":"375","author":"Hayek","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.03.006_b0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.15585\/mmwr.mm7038e2","article-title":"Use of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: recommendations of the advisory committee on immunization practices - United States, September 2021","volume":"70","author":"Dooling","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.03.006_b0030","unstructured":"NIH. COVID-19 SeroHub. https:\/\/covid19serohub.nih.gov\/ (accessed March 8, 2023)."},{"key":"10.1016\/j.vaccine.2023.03.006_b0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/EDE.0000000000001088","article-title":"Test-negative designs: differences and commonalities with other case-control studies with \u201cOther Patient\u201d controls","volume":"30","author":"Vandenbroucke","year":"2019","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2023.03.006_b0040","unstructured":"The COVID-19 Community Research Partnership: a multistate surveillance platform for characterizing the epidemiology of the SARS-CoV-2 pandemic. Biol Methods Protoc 2022; 7: bpac033."},{"key":"10.1016\/j.vaccine.2023.03.006_b0045","unstructured":"Wake Forest University Health S. A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.03.006_b0050","unstructured":"FDA. EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG). 2020. https:\/\/www.fda.gov\/media\/137609\/download (accessed April 16, 2022)"},{"key":"10.1016\/j.vaccine.2023.03.006_b0055","unstructured":"FDA. Elecsys Anti-SARS-CoV-2. 2020. https:\/\/www.fda.gov\/media\/137605\/download (accessed April 16, 2022)"},{"key":"10.1016\/j.vaccine.2023.03.006_b0060","doi-asserted-by":"crossref","unstructured":"Walker Gregory J, Davis R, Naing Z, McEntee B, Lu Y, Denadija T, et al. Serological detection of SARS-CoV-2 IgG using commercially available enzyme immunoassays on dried blood spots collected from patients. Microbiol Spectrum. 9:e01245-21.","DOI":"10.1128\/Spectrum.01245-21"},{"key":"10.1016\/j.vaccine.2023.03.006_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12874-021-01256-3","article-title":"Fast and optimal algorithm for case-control matching using registry data: application on the antibiotics use of colorectal cancer patients","volume":"21","author":"Mamouris","year":"2021","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.vaccine.2023.03.006_b0070","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0075","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0080","unstructured":"CDC. Grading of recommendations, assessment, development, and evaluation (GRADE): moderna COVID-19 vaccine; 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/bla-covid-19-moderna-vaccine.html (accessed March 8, 2023)."},{"key":"10.1016\/j.vaccine.2023.03.006_b0085","doi-asserted-by":"crossref","first-page":"e0278624","DOI":"10.1371\/journal.pone.0278624","article-title":"Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: a rapid systematic review and meta-analysis of non-randomized studies","volume":"17","author":"Wallace","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.03.006_b0090","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0095","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2021.15161","article-title":"Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021","volume":"326","author":"Jones","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.03.006_b0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3201\/eid2803.211885","article-title":"Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications","volume":"28","author":"Stone","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.006_b0105","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jir015","article-title":"Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures","volume":"203","author":"Petrie","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.006_b0110","doi-asserted-by":"crossref","unstructured":"Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1284\u201390.","DOI":"10.15585\/mmwr.mm7037e1"},{"key":"10.1016\/j.vaccine.2023.03.006_b0115","doi-asserted-by":"crossref","unstructured":"Peluso Michael J, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer Nikita S, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 7:eabh3409.","DOI":"10.1126\/sciadv.abh3409"},{"key":"10.1016\/j.vaccine.2023.03.006_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert Peter","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.03.006_b0125","doi-asserted-by":"crossref","unstructured":"Whitaker HJ, Gower C, Otter AD, Simmons R, Kirsebom F, Letley L, et al. Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off. medRxiv. 2021:2021.10.25.21264964.","DOI":"10.1101\/2021.10.25.21264964"},{"key":"10.1016\/j.vaccine.2023.03.006_b0130","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/EDE.0000000000001366","article-title":"Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines","volume":"32","author":"Lewnard","year":"2021","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2023.03.006_b0140","unstructured":"WHO. Evaluation of COVID-19 vaccine effectiveness: Interim Guidance. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1 (accessed March 5, 2022)."},{"key":"10.1016\/j.vaccine.2023.03.006_b0145","series-title":"Vaccines: Past, Present, and Future. Infectious disease epidemiology","first-page":"273","year":"2014"},{"key":"10.1016\/j.vaccine.2023.03.006_b0150","article-title":"Self-reported mask use among persons with or without SARS CoV-2 vaccination \u2014United States, December 2020\u2013August 2021","volume":"28","author":"Calamari","year":"2022","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.vaccine.2023.03.006_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10071016","article-title":"Self-reported SARS-CoV-2 vaccination is consistent with electronic health record data among the COVID-19 community research partnership","volume":"10","author":"Tjaden","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.03.006_b0160","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMe2113151","article-title":"Covid-19 vaccine effectiveness and the test-negative design","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0165","first-page":"kwac015","article-title":"Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines","author":"Kahn","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.03.006_b0170","doi-asserted-by":"crossref","unstructured":"Siddiqui Sameed M, Bowman Kathryn A, Zhu Alex L, Fischinger S, Beger S, Maron Jenny S, et al. Serological markers of SARS-CoV-2 reinfection. mBio.13:e02141-21.","DOI":"10.1128\/mbio.02141-21"},{"key":"10.1016\/j.vaccine.2023.03.006_b0175","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0180","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S1473-3099(20)30631-9","article-title":"SeroTracker: a global SARS-CoV-2 seroprevalence dashboard","volume":"21","author":"Arora","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.006_b0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.03.006_b0190","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.03.006_b0195","doi-asserted-by":"crossref","unstructured":"Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, et al. Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial. medRxiv. 2022:2022.04.18.22271936.","DOI":"10.1101\/2022.04.18.22271936"},{"key":"10.1016\/j.vaccine.2023.03.006_b0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(20)30985-3","article-title":"Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study","volume":"21","author":"Marks","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.006_b0205","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jiac318","article-title":"Coronavirus disease 2019 vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 infection in the united states before the delta- and omicron-associated surges: a retrospective cohort study of repeat blood donors","volume":"226","author":"Grebe","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.006_b0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.03.006_b0215","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-2600(22)00101-1","article-title":"Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case\u2013control study","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2023.03.006_b0220","unstructured":"CDC Recommends the First Updated COVID-19 Booster. Centers for Disease Control and Prevention 2022. https:\/\/www.cdc.gov\/media\/releases\/2022\/s0901-covid-19-booster.html (accessed September 18, 2022)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:48Z","timestamp":1759404348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002530"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March\u2013October, 2021","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}